Trial reportNutrients2024
The Effect of Carnosine Supplementation on Musculoskeletal Health in Adults with Prediabetes and Type 2 Diabetes: A Secondary Analysis of a Randomized Controlled Trial.
Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02917928 (The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes: a Randomsied, Double-blinded, Placebo-controlled Trial
Who cites it
4 citing papers in PubMed.
- Article
- Novel progress in the application of the small molecule drug carnosine for the treatment of several diseases (Review).International journal of molecular medicine · 2025Review
- Histidine-Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
- Do Preparation Techniques Transform the Metabolite Profile of Platelet-Rich Plasma?Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesType 2 diabetes (T2D) is associated with an increased risk of adverse musculoskeletal outcomes likely due to heightened chronic inflammation, oxidative stress, and advanced glycation end-products (AGE). Carnosine has been shown to have anti-inflammatory, anti-oxidative, and anti-AGE properties. However, no clinical trials have examined the impact of carnosine on musculoskeletal health in adults with prediabetes or T2D.
methodsIn a randomized, double-blind clinical trial, 49 participants with prediabetes or T2D and without existing musculoskeletal conditions were assigned to receive either 2 g/day carnosine or matching placebo for 14 weeks. Whole-body dual-energy X-ray absorptiometry (DXA) was used to assess body composition, and peripheral quantitative computed tomography (pQCT) was used to assess bone health at the distal and proximal tibia.
resultsForty-three participants completed this study. Carnosine supplementation had no effect on change in hand grip strength (HGS) or upper-limb relative strength (HGS/lean mass) versus placebo. Change in appendicular lean mass, percentage of body fat, visceral fat area, proximal tibial cortical volumetric bone mineral density (vBMD), distal tibial trabecular vBMD, and stress-strain index did not differ with carnosine compared to placebo. Fourteen weeks of carnosine supplementation did not improve muscle strength, body composition, or bone health in adults with prediabetes or T2D.
conclusionsCarnosine supplementation may not be an effective approach for improving musculoskeletal health in adults with prediabetes and T2D without musculoskeletal conditions. However, appropriately powered trials with longer duration are warranted to confirm our findings. The trial was registered at clinicaltrials.gov (NCT02917928).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.